

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

<https://marketpublishers.com/r/G555FE952545EN.html>

Date: February 2025

Pages: 153

Price: US\$ 5,950.00 (Single User License)

ID: G555FE952545EN

Abstracts

This report can be delivered to the clients within 3 Business Days

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends

The global GLP-1 agonists weight loss drugs market size is anticipated to reach USD 48.84 billion by 2030 and is projected to grow at a CAGR of 18.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared to other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.

The introduction of oral versions would not only make these therapies more accessible but also broaden the patient base who prefer non-injection-based therapies. Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access to the medications but also patient education and ongoing support for those managing obesity. Retail

pharmacies' ability to offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss. While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition to long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift to retail or specialty pharmacies. These pharmacies play a vital role in providing continued access to therapy and offering specialized services.

Specialty pharmacies and online pharmacies are also becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access to weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education to optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity to improve accessibility and adherence, providing a new avenue for pharmaceutical companies to cater to a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights

Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.

Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable

therapies, administered either weekly or bi-weekly, are preferred due to their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.

Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.

North America accounted for the largest market share in 2024, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
 - 1.3.1. Information Procurement
 - 1.3.2. Information or Data Analysis
 - 1.3.3. Market formulation & Data Visualization
 - 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
 - 1.4.1. List of Data Sources

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

CHAPTER 3. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Parent Market Outlook
- 3.2. Ancillary Market Outlook
- 3.3. Market Dynamics
 - 3.3.1. Market Drivers Analysis
 - 3.3.1.1. Rising prevalence of obesity
 - 3.3.1.2. Increasing adoption of weight loss drug therapy
 - 3.3.1.3. Rising geriatric population
 - 3.3.2. Market Restraints Analysis
 - 3.3.2.1. High cost of treatment
 - 3.3.2.2. Stringent regulations pertaining to production and approvals
- 3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
 - 3.4.1. Porter's Analysis
 - 3.4.1.1. Bargaining power of the suppliers
 - 3.4.1.2. Bargaining power of the buyers
 - 3.4.1.3. Threats of substitution
 - 3.4.1.4. Threats from new entrants

- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
 - 3.4.2.1. Political landscape
 - 3.4.2.2. Economic and Social Landscape
 - 3.4.2.3. Technological Landscape
 - 3.4.2.4. Environmental Landscape
 - 3.4.2.5. Legal Landscape

CHAPTER 4. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: BY DRUG ESTIMATES & TREND ANALYSIS

- 4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
- 4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
- 4.3. Semaglutide (Wegovy)
 - 4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Liraglutide (Saxenda)
 - 4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Tirzepatide (Zepbound)
 - 4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Other Drugs
 - 4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 5. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: BY ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

- 5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
- 5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
- 5.3. Parenteral
 - 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Oral
 - 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 6. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS

6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard

6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)

6.3. Hospital Pharmacies

6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

6.4. Retail Pharmacies

6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

6.5. Other Pharmacies

6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. GLP-1 AGONISTS WEIGHT LOSS DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)

7.2. North America

7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.2. U.S.

7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.3. Canada

7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.2.4. Mexico

7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3. Europe

7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.2. UK

7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts,

2018 - 2030 (USD Million)

7.3.3. Germany

7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.4. France

7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.5. Italy

7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.6. Spain

7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018– 2030 (USD Million)

7.3.7. Denmark

7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.8. Norway

7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.3.9. Sweden

7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4. Asia Pacific

7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.2. China

7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.3. Japan

7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.4. India

7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.5. South Korea

7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.4.6. Australia

7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and

Forecasts, 2018 - 2030 (USD Million)

7.4.7. Thailand

7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5. Latin America

7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.2. Brazil

7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.3. Argentina

7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6. Middle East and Africa

7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 – 2030 (USD Million)

7.6.2. Saudi Arabia

7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.3. UAE

7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.4. Kuwait

7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.5. South Africa

7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis by Key Market Participants

8.2. Company Categorization

8.3. Company Market Share Analysis, 2024

8.4. Company Heat Map Analysis, 2024

8.5. Company Profiles

8.5.1. Eli Lilly and Company.

8.5.1.1. Participant's Overview

8.5.1.2. Financial Performance

- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Recent Developments/ Strategic Initiatives
- 8.5.2. Pfizer Inc.
 - 8.5.2.1. Participant's Overview
 - 8.5.2.2. Financial Performance
 - 8.5.2.3. Product Benchmarking
 - 8.5.2.4. Recent Developments/ Strategic Initiatives
- 8.5.3. Novo Nordisk A/S
 - 8.5.3.1. Participant's Overview
 - 8.5.3.2. Financial Performance
 - 8.5.3.3. Product Benchmarking
 - 8.5.3.4. Recent Developments/ Strategic Initiatives
- 8.5.4. Viking Therapeutics
 - 8.5.4.1. Participant's Overview
 - 8.5.4.2. Financial Performance
 - 8.5.4.3. Product Benchmarking
 - 8.5.4.4. Recent Developments/ Strategic Initiatives
- 8.5.5. Structure Therapeutics
 - 8.5.5.1. Participant's Overview
 - 8.5.5.2. Financial Performance
 - 8.5.5.3. Product Benchmarking
 - 8.5.5.4. Recent Developments/ Strategic Initiatives

I would like to order

Product name: GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/G555FE952545EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G555FE952545EN.html>